Understanding sex differences in long-term outcomes after a first episode of psychosis

NPJ Schizophrenia
Rosa Ayesa-ArriolaBenedicto Crespo-Facorro

Abstract

While sex differences in schizophrenia have long been reported and discussed, long-term sex differences in outcomes among first episode of psychosis (FEP) patients in terms of the efficacy of Early Intervention Services (EIS) has been an under-explored area. A total of 209 FEP patients (95 females and 114 males) were reassessed after a time window ranging from 8 to 16 years after their first contact with an EIS program (PAFIP) that we will call the 10-year PAFIP cohort. Multiple clinical, cognitive, functioning, premorbid, and sociodemographic variables were explored at 1-year, 3-year and 10-year follow-ups. At first contact, females were older at illness onset, had higher premorbid adjustment and IQ, and were more frequently employed, living independently, and accompanied by a partner and/or children. Existence of a schizophrenia diagnosis, and cannabis and alcohol consumption were more probable among men. During the first 3 years, women showed a significantly better response to minimal antipsychotic dosages and higher rates of recovery than men (50% vs. 30.8%). Ten years later, more females continued living independently and had partners, while schizophrenia diagnoses and cannabis consumption continued to be more frequent amo...Continue Reading

References

Mar 1, 1992·Schizophrenia Research·D AddingtonJ Joyce
Jan 1, 1990·Schizophrenia Bulletin·R E Gur, R C Gur
Jun 1, 1973·Psychological Reports·A Flemenbaum, R L Zimmermann
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1982·Schizophrenia Bulletin·H E Cannon-SpoorR J Wyatt
Aug 5, 1998·Schizophrenia Research·B S GrubeR S Goldman
Mar 26, 2003·Psychoneuroendocrinology·H Häfner
Aug 3, 2004·The American Journal of Psychiatry·Mary V Seeman
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Feb 10, 2007·Psychological Medicine·Anne ThorupMerete Nordentoft
May 23, 2008·Schizophrenia Bulletin·Abraham ReichenbergEvelyn Bromet
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Nov 5, 2010·International Review of Psychiatry·Kathryn M AbelJill M Goldstein
Jan 26, 2011·The Australian and New Zealand Journal of Psychiatry·Wing Chung ChangEric Y H Chen
Feb 12, 2013·European Psychiatry : the Journal of the Association of European Psychiatrists·A ThorupM Nordentoft
Oct 1, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Rosa Ayesa-ArriolaBenedicto Crespo-Facorro
May 9, 2014·JAMA Psychiatry·Carsten Bøcker PedersenWilliam W Eaton
Nov 25, 2016·Neuropsychiatric Disease and Treatment·Diego NovickJosep Maria Haro
Mar 10, 2017·Schizophrenia Research·Regitze Sølling WilsMerete Nordentoft
Nov 15, 2018·World Journal of Psychiatry·Mary V Seeman
Nov 30, 2018·The Psychiatric Quarterly·Mary V Seeman
Mar 30, 2019·Frontiers in Neuroendocrinology·Jayashri KulkarniAnita Riecher-Rössler
May 12, 2019·Neuropharmacology·Mary V Seeman
May 3, 2020·NPJ Schizophrenia·Iris E SommerHeidi Taipale

❮ Previous
Next ❯

Citations

Mar 4, 2021·Expert Review of Neurotherapeutics·Mary V Seeman
May 7, 2021·Psychological Medicine·Rosa Ayesa-ArriolaBenedicto Crespo-Facorro

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02534363

Software Mentioned

PAFIP
Statistical Package for Social Science

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here